We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.

AusPAR: Olmesartan medoxomil / Amlodipine (as besilate) / Hydrochlorothiazide

Australian Public Assessment Report

AusPAR

AusPAR: Olmesartan medoxomil / Amlodipine (as besilate) / Hydrochlorothiazide [PDF, 916.67 KB]

AusPAR: Olmesartan medoxomil / Amlodipine (as besilate) / Hydrochlorothiazide [DOCX, 1.71 MB]

Attachment: Product Information: Olmesartan medoxomil / Amlodipine (as besilate) / Hydrochlorothiazide [PDF, 413.23 KB]

Attachment: Product Information: Olmesartan medoxomil / Amlodipine (as besilate) / Hydrochlorothiazide [DOCX, 290.41 KB]

Attachment: Extract from Clinical Evaluation Report: Olmesartan medoxomil / Amlodipine (as besilate) / Hydrochlorothiazide [PDF, 1.77 MB]

Attachment: Extract from Clinical Evaluation Report: Product Information: Olmesartan medoxomil / Amlodipine (as besilate) / Hydrochlorothiazide [DOCX, 2.86 MB]

Device/Product Name

Sevikar HCT

Active ingredients

Olmesartan medoxomil / Amlodipine (as besilate) / Hydrochlorothiazide

AusPAR Date

18 November 2013

Published

23 December 2013

Submission Number

PM-2012-01550-3-3

Submission Type

New fixed dose combination

Decision

Approved

Product types

Prescription medicines